These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 20848453)

  • 41. Budesonide CIR capsules (once or twice daily divided-dose) in active Crohn's disease: a randomized placebo-controlled study in the United States.
    Tremaine WJ; Hanauer SB; Katz S; Winston BD; Levine JG; Persson T; Persson A;
    Am J Gastroenterol; 2002 Jul; 97(7):1748-54. PubMed ID: 12135030
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Randomised trial and open-label extension study of an anti-interleukin-6 antibody in Crohn's disease (ANDANTE I and II).
    Danese S; Vermeire S; Hellstern P; Panaccione R; Rogler G; Fraser G; Kohn A; Desreumaux P; Leong RW; Comer GM; Cataldi F; Banerjee A; Maguire MK; Li C; Rath N; Beebe J; Schreiber S
    Gut; 2019 Jan; 68(1):40-48. PubMed ID: 29247068
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Oral Pentasa in the treatment of active Crohn's disease: A meta-analysis of double-blind, placebo-controlled trials.
    Hanauer SB; Strömberg U
    Clin Gastroenterol Hepatol; 2004 May; 2(5):379-88. PubMed ID: 15118975
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Teduglutide, a novel mucosally active analog of glucagon-like peptide-2 (GLP-2) for the treatment of moderate to severe Crohn's disease.
    Buchman AL; Katz S; Fang JC; Bernstein CN; Abou-Assi SG;
    Inflamm Bowel Dis; 2010 Jun; 16(6):962-73. PubMed ID: 19821509
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Onercept for moderate-to-severe Crohn's disease: a randomized, double-blind, placebo-controlled trial.
    Rutgeerts P; Sandborn WJ; Fedorak RN; Rachmilewitz D; Tarabar D; Gibson P; Haagen Nielsen O; Wild G; Schreiber S; Pena Rossi C; Zignani M;
    Clin Gastroenterol Hepatol; 2006 Jul; 4(7):888-93. PubMed ID: 16797249
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Randomized, double-blind, placebo-controlled trial of the oral interleukin-12/23 inhibitor apilimod mesylate for treatment of active Crohn's disease.
    Sands BE; Jacobson EW; Sylwestrowicz T; Younes Z; Dryden G; Fedorak R; Greenbloom S
    Inflamm Bowel Dis; 2010 Jul; 16(7):1209-18. PubMed ID: 19918967
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial.
    Sandborn WJ; Hanauer SB; Rutgeerts P; Fedorak RN; Lukas M; MacIntosh DG; Panaccione R; Wolf D; Kent JD; Bittle B; Li J; Pollack PF
    Gut; 2007 Sep; 56(9):1232-9. PubMed ID: 17299059
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Efficacy and Safety of Upadacitinib in a Randomized Trial of Patients With Crohn's Disease.
    Sandborn WJ; Feagan BG; Loftus EV; Peyrin-Biroulet L; Van Assche G; D'Haens G; Schreiber S; Colombel JF; Lewis JD; Ghosh S; Armuzzi A; Scherl E; Herfarth H; Vitale L; Mohamed MF; Othman AA; Zhou Q; Huang B; Thakkar RB; Pangan AL; Lacerda AP; Panes J
    Gastroenterology; 2020 Jun; 158(8):2123-2138.e8. PubMed ID: 32044319
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Mongersen, an oral SMAD7 antisense oligonucleotide, and Crohn's disease.
    Monteleone G; Neurath MF; Ardizzone S; Di Sabatino A; Fantini MC; Castiglione F; Scribano ML; Armuzzi A; Caprioli F; Sturniolo GC; Rogai F; Vecchi M; Atreya R; Bossa F; Onali S; Fichera M; Corazza GR; Biancone L; Savarino V; Pica R; Orlando A; Pallone F
    N Engl J Med; 2015 Mar; 372(12):1104-13. PubMed ID: 25785968
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial.
    Hanauer SB; Sandborn WJ; Rutgeerts P; Fedorak RN; Lukas M; MacIntosh D; Panaccione R; Wolf D; Pollack P
    Gastroenterology; 2006 Feb; 130(2):323-33; quiz 591. PubMed ID: 16472588
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Long-term safety and efficacy of adalimumab in Japanese patients with moderate to severe Crohn's disease.
    Watanabe M; Hibi T; Mostafa NM; Chao J; Arora V; Camez A; Petersson J; Thakkar R
    J Crohns Colitis; 2014 Nov; 8(11):1407-16. PubMed ID: 24874893
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A randomised, double-blind, sham-controlled study of granulocyte/monocyte apheresis for moderate to severe Crohn's disease.
    Sands BE; Katz S; Wolf DC; Feagan BG; Wang T; Gustofson LM; Wong C; Vandervoort MK; Hanauer S
    Gut; 2013 Sep; 62(9):1288-94. PubMed ID: 22760005
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Natalizumab induction and maintenance therapy for Crohn's disease.
    Sandborn WJ; Colombel JF; Enns R; Feagan BG; Hanauer SB; Lawrance IC; Panaccione R; Sanders M; Schreiber S; Targan S; van Deventer S; Goldblum R; Despain D; Hogge GS; Rutgeerts P; ;
    N Engl J Med; 2005 Nov; 353(18):1912-25. PubMed ID: 16267322
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Serum calprotectin as a biomarker for Crohn's disease.
    Meuwis MA; Vernier-Massouille G; Grimaud JC; Bouhnik Y; Laharie D; Piver E; Seidel L; Colombel JF; Louis E;
    J Crohns Colitis; 2013 Dec; 7(12):e678-83. PubMed ID: 23845231
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Mesalamine capsules for the treatment of active Crohn's disease: results of a 16-week trial. Pentasa Crohn's Disease Study Group.
    Singleton JW; Hanauer SB; Gitnick GL; Peppercorn MA; Robinson MG; Wruble LD; Krawitt EL
    Gastroenterology; 1993 May; 104(5):1293-301. PubMed ID: 8482443
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pharmacokinetics and exposure-efficacy relationship of adalimumab in pediatric patients with moderate to severe Crohn's disease: results from a randomized, multicenter, phase-3 study.
    Sharma S; Eckert D; Hyams JS; Mensing S; Thakkar RB; Robinson AM; Rosh JR; Ruemmele FM; Awni WM
    Inflamm Bowel Dis; 2015 Apr; 21(4):783-92. PubMed ID: 25723614
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease.
    Ito H; Takazoe M; Fukuda Y; Hibi T; Kusugami K; Andoh A; Matsumoto T; Yamamura T; Azuma J; Nishimoto N; Yoshizaki K; Shimoyama T; Kishimoto T
    Gastroenterology; 2004 Apr; 126(4):989-96; discussion 947. PubMed ID: 15057738
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Steroid-sparing properties of sargramostim in patients with corticosteroid-dependent Crohn's disease: a randomised, double-blind, placebo-controlled, phase 2 study.
    Valentine JF; Fedorak RN; Feagan B; Fredlund P; Schmitt R; Ni P; Humphries TJ
    Gut; 2009 Oct; 58(10):1354-62. PubMed ID: 19505878
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials.
    Panés J; Sandborn WJ; Schreiber S; Sands BE; Vermeire S; D'Haens G; Panaccione R; Higgins PDR; Colombel JF; Feagan BG; Chan G; Moscariello M; Wang W; Niezychowski W; Marren A; Healey P; Maller E
    Gut; 2017 Jun; 66(6):1049-1059. PubMed ID: 28209624
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Oral administration of non-absorbable delayed release 6-mercaptopurine is locally active in the gut, exerts a systemic immune effect and alleviates Crohn's disease with low rate of side effects: results of double blind Phase II clinical trial.
    Israeli E; Goldin E; Fishman S; Konikoff F; Lavy A; Chowers Y; Melzer E; Lahat A; Mahamid M; Shirin H; Nussinson E; Segol O; Ya'acov AB; Shabbat Y; Ilan Y
    Clin Exp Immunol; 2015 Aug; 181(2):362-72. PubMed ID: 25846055
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.